This is the site where you describe potential projects you would like to undertake as an academic collaboration, commercial service or other matters.

Ongoing projects

1. Design of a recombinant vaccine against a human pathogen

Project is funded by the Polish National Science Center in OPUS 11, Panel 6. It was judged as the second best project in the group in Poland.

Goal of the project is to design a recombinant vaccine against a given pathogen causing periodontosis. It relies on rewiring metabolic pathways of E. coli for production of components needed for the vaccine candidate. The work is a combination of systems biology, genetic engineering, protein manipulation and finally animal studies. The last part is going to be performed by our collaborator in Poland.

Technology can be re-purposed for vaccine design against any pathogen and completely bypasses carrier coupling in the final product.

2. Small molecule inhibitors of bacterial virulence

The project relies on systems analysis and computational modeling to design small molecules blocking bacterial virulence. Theoretically, the offensive weaponry of pathogen is disabled and the bacteria are destroyed by the host’s immune system.

Existing solutions are designed in-house and tested on many pathogens of public health concern. Project is aided by Schroedinger’s suite of computational modeling tools, in-house solutions and a collaboration with an external company. Best candidates are fully functional, potent and waiting for the next step.

3. Antibacterial and antifungal compounds

This part is done in collaboration with an external company. Existing solutions are fully capable of blocking growth of selected pathogens, destroying them or simply disabling their ability to destroy human cells. Examples are in the Technology section under References.

Due to draconian animal protection laws in Poland, animal studies have to be performed somewhere else. Testing in animals would require signing proper documents for MTA and IP protection laws.

4. Computational drug design

This part is done in-house using in-house and external computational resources. Many of the computational tools are beyond EU borders and have to be used on a pay-per-use basis.